empty
 
 
nl
Search
Ondersteuning
Direct openen van een account
Trading Platform
Storting/opname
Search
Voor beginners Voor traders Voor partners Neem een ​​pauze About InstaSpot
nl
For Traders
Charts
#ALNY

#ALNY (Alnylam Pharmaceuticals Inc.). Wisselkoers en online grafieken.

#ACB Terug naar de lijst met instrumenten #AMGN

Valuta converter

Alnylam Pharmaceuticals Inc.
240.1 USD
09 Jan 2025 18:08
Prijsverandering (% chg)
$0
(0%)
Vorige close
Vorige close

Sluitprijs, de vorige dag.
$240.1
Open
Open

Openingsprijs.
$234.37
Hoog dag
Hoog dag

Hoogste prijs over vorige trading dag.
$240.1
Laag dag
Laag dag

De laagste prijs voor de laatste handelsdag
$240.1
52-wk Hoog
52-wk Hoog

Prijsklasse hoog in de laatste 52 weken
$240.1
52-wk Laag
52-wk Laag

Prijsklasse laag in de laatste 52 weken
$234
Download archief
Buy
240.1
Sell
240.1
Open the chart in full screen view
Buy
240.1
Sell
240.1
Download archief
Open the chart in full screen view

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Kan u nu niet praten?
Stel uw vraag in de chat.